Transcriptional Regulation in Cancers and Metabolic Diseases
The transcription factor (TF) mediated regulation of gene expression is a process fundamental to all biological and physiological processes. Genetic changes and epigenetic modifications of TFs affect target gene expression during the formation of malignant cells. Extensive work has been done on the...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Media SA
2021
|
| Subjects: | |
| Online Access: | 18833 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869514263054254080 |
|---|---|
| author | Carol Prives Wen Zhou |
| author_browse | Carol Prives Wen Zhou |
| author_facet | Carol Prives Wen Zhou |
| author_sort | Carol Prives |
| collection | Directory of Open Access Books |
| description | The transcription factor (TF) mediated regulation of gene expression is a process fundamental to all biological and physiological processes. Genetic changes and epigenetic modifications of TFs affect target gene expression during the formation of malignant cells. Extensive work has been done on the critical TFs in various disease models. Despite the success of numerous TF-targeted therapies, there remain significant hurdles understanding the mechanisms, transcriptional targets and networks of physiologic pathways that govern TF action. This effort is now beginning to produce exciting new avenues of research. A clinically relevant topic for genetic change of TF is the mutant isoforms of p53, the most famous tumor suppressor. The p53 mutations either results in loss of function, or acting as dominant negative for wild-type protein, or ‘gain of function’ specifically promoting cancer survival. The gain of function is achieved by shifting p53 binding partner proteins, or changed genomic binding landscape leading to a cancer-promoting transcriptome. Another example of genetic change of TF causing malignancy is the AML-ETO fusion protein in the human t(8;21)-leukemia. The fusion protein is an active TF, and more interestingly, new studies link the disease causing role of AML-ETO to the unique transcriptome in the hematopoietic stem cells. Nuclear receptors (NR) are a group of ligand-dependent TFs governing the expression of genes involved in a broad range of reproductive, developmental and metabolic programs. Genetic changes and epigenetic modifications of NRs lead to cancers and metabolic diseases. Androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) are well studied NRs in prostate, breast and endometrial cancers. The development in sequencing technology and computational genomics enable us to investigate the transcription programs of these master TFs in an unprecedented level. This Research Topic aims to present the most up-to-date progress in the field of transcription regulation in cancers and metabolic diseases. |
| format | Online |
| id | doab-20.500.12854ir-61176 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-611762024-03-30T23:21:36Z Transcriptional Regulation in Cancers and Metabolic Diseases Carol Prives Wen Zhou R5-920 RC648-665 RC254-282 senescence Cell Cycle Cancer stem cell nuclear receptor microRNA p63 exosome tran epigenetics p53 thema EDItEUR::M Medicine and Nursing The transcription factor (TF) mediated regulation of gene expression is a process fundamental to all biological and physiological processes. Genetic changes and epigenetic modifications of TFs affect target gene expression during the formation of malignant cells. Extensive work has been done on the critical TFs in various disease models. Despite the success of numerous TF-targeted therapies, there remain significant hurdles understanding the mechanisms, transcriptional targets and networks of physiologic pathways that govern TF action. This effort is now beginning to produce exciting new avenues of research. A clinically relevant topic for genetic change of TF is the mutant isoforms of p53, the most famous tumor suppressor. The p53 mutations either results in loss of function, or acting as dominant negative for wild-type protein, or ‘gain of function’ specifically promoting cancer survival. The gain of function is achieved by shifting p53 binding partner proteins, or changed genomic binding landscape leading to a cancer-promoting transcriptome. Another example of genetic change of TF causing malignancy is the AML-ETO fusion protein in the human t(8;21)-leukemia. The fusion protein is an active TF, and more interestingly, new studies link the disease causing role of AML-ETO to the unique transcriptome in the hematopoietic stem cells. Nuclear receptors (NR) are a group of ligand-dependent TFs governing the expression of genes involved in a broad range of reproductive, developmental and metabolic programs. Genetic changes and epigenetic modifications of NRs lead to cancers and metabolic diseases. Androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) are well studied NRs in prostate, breast and endometrial cancers. The development in sequencing technology and computational genomics enable us to investigate the transcription programs of these master TFs in an unprecedented level. This Research Topic aims to present the most up-to-date progress in the field of transcription regulation in cancers and metabolic diseases. 2021-02-12T06:21:24Z 2021-02-12T06:21:24Z 2016-04-07 11:22:02 2015 book 18833 16648714 9782889197125 https://directory.doabooks.org/handle/20.500.12854/61176 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Transcriptional_Regulation_in_Cancers_and_Metabolic_Diseases/732#nogo http://journal.frontiersin.org/researchtopic/3283/transcriptional-regulation-in-cancers-and-metabolic-diseases Frontiers Media SA 10.3389/978-2-88919-712-5 10.3389/978-2-88919-712-5 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889197125 98 open access |
| spellingShingle | R5-920 RC648-665 RC254-282 senescence Cell Cycle Cancer stem cell nuclear receptor microRNA p63 exosome tran epigenetics p53 thema EDItEUR::M Medicine and Nursing Carol Prives Wen Zhou Transcriptional Regulation in Cancers and Metabolic Diseases |
| title | Transcriptional Regulation in Cancers and Metabolic Diseases |
| title_full | Transcriptional Regulation in Cancers and Metabolic Diseases |
| title_fullStr | Transcriptional Regulation in Cancers and Metabolic Diseases |
| title_full_unstemmed | Transcriptional Regulation in Cancers and Metabolic Diseases |
| title_short | Transcriptional Regulation in Cancers and Metabolic Diseases |
| title_sort | transcriptional regulation in cancers and metabolic diseases |
| topic | R5-920 RC648-665 RC254-282 senescence Cell Cycle Cancer stem cell nuclear receptor microRNA p63 exosome tran epigenetics p53 thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RC648-665 RC254-282 senescence Cell Cycle Cancer stem cell nuclear receptor microRNA p63 exosome tran epigenetics p53 thema EDItEUR::M Medicine and Nursing |
| url | 18833 |
| work_keys_str_mv | AT carolprives transcriptionalregulationincancersandmetabolicdiseases AT wenzhou transcriptionalregulationincancersandmetabolicdiseases |